The survival benefit of adjuvant trastuzumab with or without chemotherapy in the management of small (T1mic, T1a, T1b, T1c), node negative HER2+ breast cancer.

Autor: Johnson KCC; The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA., Ni A; Division of Biostatistics, The Ohio State University College of Public Health, Columbus, OH, USA., Quiroga D; The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA., Pariser AC; The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA., Sudheendra PK; The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA., Williams NO; The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA., Sardesai SD; The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA., Cherian M; The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA., Stover DG; The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA., Gatti-Mays M; The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA., Ramaswamy B; The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA., Lustberg M; Smilow Cancer Hospital, Yale Cancer Center, New Haven, CT, USA., Jhawar S; The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA., Skoracki R; The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA., Wesolowski R; The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA. Robert.Wesolowski@osumc.edu.
Jazyk: angličtina
Zdroj: NPJ breast cancer [NPJ Breast Cancer] 2024 Jun 19; Vol. 10 (1), pp. 49. Date of Electronic Publication: 2024 Jun 19.
DOI: 10.1038/s41523-024-00652-4
Abstrakt: There is limited data regarding the added benefit of adjuvant systemic therapy in the management of small, node-negative, HER2+ breast cancer. In a multi-institutional retrospective analysis using the American Society of Clinical Oncology CancerLinQ database, we compared survival outcomes among T1a-c N0 HER2+ patients diagnosed between 2010 to 2021 who received locoregional therapy alone or in combination with adjuvant trastuzumab (+/- chemotherapy). Primary outcomes were invasive disease-free survival (iDFS) and overall survival (OS). Of the 1,184 patients, 436 received locoregional therapy alone. We found a statistically significant improvement in iDFS (HR 0.73, P = 0.003) and OS (HR 0.63, P = 0.023) on univariate analysis with adjuvant trastuzumab with or without chemotherapy which remained statistically significant on multivariate analysis. Three-arm univariate analysis found that iDFS was significantly improved with trastuzumab monotherapy (P = 0.003) and combination therapy (P = 0.027) compared to observation. Subgroup data suggests that T1b/c tumors derive the greatest benefit.
(© 2024. The Author(s).)
Databáze: MEDLINE
Externí odkaz: